指南与共识消化、代谢与肾脏急症儿科与产科急症

超越专家意见:妊娠期尿路感染抗生素方案的比较

Beyond Expert Opinion: A Comparison of Antibiotic Regimens for Infectious Urinary Tract Pathology in Pregnancy.
指南 / 共识 · AJP Rep · 2020-10-12
一句话结论回顾性队列显示妊娠期下尿路感染使用非一线抗生素(非呋喃妥因或SMZ-TMP)与进展为肾盂肾炎、早产或低出生体重风险增加无关。

该单中心回顾性队列纳入2013年7月至2019年5月476例妊娠期下尿路感染(含无症状菌尿和急性膀胱炎)女性,比较一线治疗(呋喃妥因或SMZ-TMP,336例)与非一线治疗(140例)。一线组进展为肾盂肾炎5.8% vs 非一线组8.2%(p=0.44),校正混杂后aOR 1.02(95%CI 0.42-2.49)。一线治疗与早产或低出生体重无关(aOR 0.60,95%CI 0.29-1.26)。结论认为妊娠期下尿路感染使用非呋喃妥因或SMZ-TMP抗生素未增加进展为肾盂肾炎、早产或低出生体重的风险。

要点

  • 妊娠期下尿路感染(含无症状菌尿和急性膀胱炎)使用非一线抗生素(非呋喃妥因或SMZ-TMP)与进展为肾盂肾炎风险无关:5.8% vs 8.2%(p=0.44),校正后aOR 1.02(95%CI 0.42-2.49)。
  • 一线治疗(呋喃妥因或SMZ-TMP)与非一线治疗相比,早产或低出生体重的校正OR为0.60(95%CI 0.29-1.26),无显著差异。
  • 肾盂肾炎相关贫血、脓毒症、住院时间等次要结局在一线组与非一线组间无差异。
  • 一线组中BMI≥40者更多(p=0.04),提示两组基线特征存在差异。
  • 研究为单中心回顾性队列,样本量476例。

适用人群与场景

  • 妊娠期下尿路感染女性,包括无症状菌尿和急性膀胱炎,2013年7月至2019年5月于单一医疗系统就诊。

研究设计与关键结果

  • 研究类型:单中心回顾性队列,纳入476例妊娠期下尿路感染女性,其中一线治疗组336例(70.6%),非一线治疗组140例(29.4%)。
  • 主要终点:进展为肾盂肾炎,一线组5.8% vs 非一线组8.2%(p=0.44),校正混杂后aOR 1.02(95%CI 0.42-2.49)。
  • 关键次要终点:早产或低出生体重,校正后aOR 0.60(95%CI 0.29-1.26);肾盂肾炎相关贫血、脓毒症、住院时间等无差异。
  • 一线组BMI≥40者更多(p=0.04)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究;原文未报告证据等级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,妊娠期下尿路感染使用非呋喃妥因或SMZ-TMP抗生素未增加进展为肾盂肾炎、早产或低出生体重的风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Objective Outside pregnancy, nitrofurantoin, ciprofloxacin and sulfamethoxazole-trimethoprim (SMZ-TMP) are first-line therapy (FLT) for lower urinary tract infections (LUTIs). Optimal antibiotics for LUTI have been extrapolated based on expert opinion. Progression to pyelonephritis and adverse obstetric outcomes were compared between women who received FLT and those given alternative antibiotics. Methods This study includes a retrospective cohort of women with LUTI, including asymptomatic bacteriuria and acute cystitis at single health care system from July 2013 to May 2019. Women receiving FLT, defined as nitrofurantoin or SMZ-TMP, were compared with those receiving nonfirst-line therapy (nFLT). Primary outcome was progression to pyelonephritis. Secondary outcomes included pyelonephritis-related anemia, sepsis, length of stay, preterm birth (PTB), and low birth weight (LBW). Logistic regression was used to calculate odds of outcomes. Results Of 476 women, 336 (70.6%) received FLT and 140 (29.4%) received nFLT. Women receiving FLT were more likely having BMI ≥ 40 ( p = 0.04). Progression to pyelonephritis did not differ (5.8 vs. 8.2%; p = 0.44), nor did other pyelonephritis-related outcomes. After controlling for confounders, no difference in odds of progression to pyelonephritis was seen (adjusted odds ratio [aOR] 1.02, 95% confidence interval [CI] 0.42, 2.49). FLT was not associated with PTB or LBW (aOR 0.60, 95% CI 0.29, 1.26) after controlling for confounders. Conclusion Receipt of antibiotics other than nitrofurantoin or SMZ-TMP for LUTI in pregnancy was not associated with increased risk of progression to pyelonephritis, PTB, or LBW.

来源:AJP Rep,查看原文。版权归原作者所有。

参考来源

  1. Krischak MK, Rosett HA, Sachdeva S, et al. Beyond Expert Opinion: A Comparison of Antibiotic Regimens for Infectious Urinary Tract Pathology in Pregnancy. AJP Rep. 2020. PMID: 33094027. doi:10.1055/s-0040-1718384

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。